ArticleMedicine2026
A nutrition-first, barrier-augmented, staged debridement management of grade IV oral mucositis in a leukemia patient with decompensated cirrhosis: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleOral mucositis (OM) is a common but serious complication of chemotherapy, particularly in patients with hematologic malignancies. Severe OM can significantly impair nutritional intake and quality of life, and may delay antileukemic therapy. This case report presents a multidisciplinary, integrative approach for managing grade IV OM in a patient with acute lymphoblastic leukemia and decompensated cirrhosis. PATIENT CONCERNS: A 63-year-old female with a 13-year history of liver cirrhosis was admitted because of abdominal pain. DIAGNOSES: Laboratory tests revealed B-cell acute lymphoblastic leukemia, pancytopenia, and hypoalbuminemia. On day 15 of chemotherapy, oral mucosal ulcerations emerged and progressed to grade IV OM by day 29, characterized by hemorrhagic eschar, intolerable pain (numeric rating scale score 6), and complete inability to eat.
interventionsA multidisciplinary management strategy was implemented. Aggressive nutritional support was initiated, combining total parenteral nutrition with early enteral feeding via a nasogastric tube using a customized, blenderized formula enriched with branched-chain amino acids and whey protein. For wound care, hemorrhagic eschar was softened daily with saline, followed by cautious debridement to minimize pain and bleeding. Montmorillonite powder was applied to the wound to form a protective mucosal barrier and reduce infection risk. Pain management and psychological support were provided to enhance treatment adherence and maintain emotional stability. OUTCOMES: On day 63, oral mucositis had fully resolved, and antileukemic therapy proceeded without further interruption. LESSONS: An integrated "nutrition-first, barrier-augmented, staged-debridement" management strategy may significantly enhance the healing of oral mucositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.